Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: Position of the World Marrow Donor Association

Haematologica

Volumn 96, Issue 7, 2011, Pages 942-947

  Shaw, Bronwen E ^a,b   Confer, Dennis L ^c   Hwang, William Y ^d,e,f   Pamphilon, Derwood H ^g   Pulsipher, Michael A ^a,h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Singapore General Hospital ^*

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f NHS BLOOD AND TRANSPLANT   (United Kingdom)

^g UNIVERSITY OF UTAH   (United States)

^h PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAYNE; PLIVA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

BONE PAIN; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; EUROPEAN UNION; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MYALGIA; NEUTROPENIA; PHARMACODYNAMICS; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

DRUG APPROVAL; EUROPEAN UNION; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; TISSUE DONORS;

EID: 79959924862     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.045740     Document Type: Editorial

References (18)

1. Who. Guidelines on evaluation of similar Biotherapeutic products (sbps). Biotherapeutics_for_web_22april2010. pdf. 2009.
2. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94(1):94-101.
3. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114(18):3757-63.
4. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604-11.
5. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colonystimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol. 2004; 32(1):122-30.
6. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006;135(5):642-50.
7. McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D, et al. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. Transfusion. 2008;48(9):2008-25.
8. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol. 2006;135(5):651-2.
9. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol. 2007;137(1):77-8; author reply 9-80.
10. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48(7):1495-501.
11. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411-9.
12. Emea. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.tga.gov.au/docs/pdf/euguide/bmwp/4283205en.pdf. 2006.
13. Emea. Guideline on similar biological medicinal products. Http://www.ema.europa.eu/docs/en_gb/document_library/scientific_guideline/2009/09/wc500003517.pdf. 2005.
14. Emea. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. http://www.tga.gov.au/docs/pdf/euguide/bmwp/3132905en.pdf. 2006.
15. Kim IH, Park SK, Suh OK, Oh JM. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opin. 2003;19(8):753-9.
16. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997;98(2):474-9.
17. Publicover A, Richardson DS, Hill K, Hurlock C, Casey P, Newman J, et al. Use of iosimilar GCSF for peripheral blood progenitor cell mobilisation prior to autologous stem cell transplantation: a single-centre experience (abstract). Bone Marrow Transplantation. 2010;45(S2):158-9.
18. Ferro HH, Juni M, Bello R, Vidal A, Diez RA, Pavlovsky S. Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfus Apher Sci. 2009;41(2):87-93.